Files
Download Full Text (425 KB)
Description
Aim: Embedded clinical pharmacists within primary care clinics optimize pharmacologic care for patients with high-risk disease states including Type 2 Diabetes Mellitus (T2DM) and established cardiovascular disease. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are two classes of evidence-based therapies for these indications. However, medication access is a common barrier for these medications due to high cost, drug shortages, and need for insurance prior authorizations. The overall goal of this initiative was to improve access and increase utilization of GLP-1 RA and SGLT2i by: Improving teamwork and communication between key internal teams to help patients access GLP-1 RA and SGLT2i; Assessing utilization of Henry Ford Pharmacies for GLP-1 RA and SGLT2i in clinics with embedded clinical pharmacists; Describing the impact of the patient care team on connecting patients to the Henry Ford Pharmacy Patient Financial Assistance Program (HF PFAP).
Publication Date
3-12-2024
Publisher
Henry Ford Health
City
Detroit, Michigan
Keywords
Quality Expo, posters, poster competition
Recommended Citation
Thomas, Emily; Jiang, Christine; Lee, Patricia; Solomon, Octavia; Kolander, Sarah; Gottschall, Terry; Lobkovich, Alison; Nair, Namitha; Nykin, Maksym; Schmitt, Kylie; Howard, Priscilla; Hammoud, Marwa; and Ridgeway, Ericka B., "Project #62: Collaboration is Key: Embedded Clinical Pharmacists in Primary Care Clinics Collaborate to Help Patients with Diabetes and Cardiovascular Risk" (2024). Quality Expo 2024. 59.
https://scholarlycommons.henryford.com/qualityexpo2024/59